Subscribe
Subscribe

Biomedical/pharma

Agrofood, Biomedical/pharma

R&D Real Estate: A Cornerstone of European Innovation

The most visible — yet often overlooked — parts of an innovative ecosystem are the buildings that house research and development activities. Far more than just office space, these physical foundations facilitate the translation of lofty ideas into tangible solutions for society. Kadans Science Partner is one of Europe’s foremost providers of this specialized infrastructure, with a unique community-minded model.

Health Innovation Funding: Spearhead Clusters Lead the Way in Flanders

BioVox spoke with Sara Van Overmeire and Annie Renders of Flanders Innovation & Entrepreneurship (VLAIO) about the origin and role of spearhead clusters. VLAIO is the Flemish government’s point of contact for all entrepreneurs in Flanders. It relies on Biovia and other spearhead clusters to bring companies together and support them in setting up innovative projects.

MeSH Counter: A Tool to Track Biomedical Research Trends

Venture investing in early-stage companies hinges on spotting transformative technologies before they become hyped. To support this, we built the MeSH Counter: an R-based tool that tracks monthly frequencies of specific terms in PubMed, allowing us to visualize trends in the life sciences. Publication trends are not the same as investment signals, yet the MeSH Counter can help efficiently map the research landscape, so investors can prioritize deeper, human-led diligence.

Belgian Biotech Agomab Debuts on Nasdaq with a $200 Million IPO

Just weeks after announcing its plans for a U.S. listing, Belgium-based Agomab Therapeutics has gone public on Nasdaq, pricing its IPO at $16 per share to raise about $200 million. The stock is now trading under the ticker AGMB, putting the spotlight on fibrosis in what has been a billion-dollar week for biotech IPOs.

Hospitals and Belgian Companies Unite to Shape the Future of Healthcare

On 29 January 2026, 400 Belgian healthcare stakeholders — hospital executives, policymakers, and innovators — gathered in Brussels to help shape the future of healthcare. The objective was to connect hospital needs with the innovative technologies developed by Belgian companies. Two projects were honored during the event’s Innovation Awards: Baby Detect and SIM BLOOD.

Dengue: A Virus Without Borders

We are all familiar with global viruses: The flu shows up every year across the world, and not long ago we collectively experienced the SARS-CoV-2 pandemic. Now, a neglected tropical disease is joining this club of viruses without borders. Dengue — also known as break-bone fever — is currently one of the world’s fastest spreading viral diseases, with more than half of the global population already at risk.

Mind Over Money: US vs. European Investment Psychology in Biotech

Early-stage biotech investing has always demanded a high tolerance for uncertainty, and an uncanny ability to predict which fledgling technologies will one day reshape health. But one silent force shapes investment outcomes more often than we admit: psychology. At the intersection of capital and culture, we find a compelling and underexplored story — the differences between investors in the US and Europe, and how these contrasts play out in biotech.

To PhD or Not to PhD: A Growing Question in the Life Sciences

An increasing number of PhD students are concerned about their career prospects. Currently, only around 5-10% of PhD graduates remain in academia — the vast majority have to navigate an unfamiliar job market, where industry demand for their highly educated profiles appears to be in decline. Is a PhD still the best route to professional success? And what can students do to prepare themselves?

European Biotech Act: New initiative to mobilize €10 billion investment for Europe’s biotech sector

The European Commission and the European Investment Bank (EIB) Group have announced an initiative to mobilize €10 billion in investment in 2026-27 into the biotech and life sciences sector. The project aims to give a significant boost to the EU's competitiveness in biotechnology, by addressing the EU's current investment gap and mobilizing public-private investment into promising new health solutions.

Celebrating the Pitch Winners of HealthTech Investor Summit 2025

Europe’s healthtech pipeline was on full display at the HealthTech Investor Summit 2025 in Utrecht, with the regions brightest rising stars in the spotlight. From surgical robotics and implantable devices to bioelectronics and next-generation diagnostics, here are the pitching companies that stood out to both the judges and audience.

Before the Fall: Catching Cognitive Decline Early with Citizen Science

In Antwerp, a unique cohort of volunteers is helping to solve one of the world's most urgent medical challenges: the early detection of cognitive decline. While the study is local, its implications are global — providing the long-term data needed to understand the hidden years of decline in Alzheimer's disease and other forms of dementia, to enable early diagnosis and intervention.

The FDA Reset and its Ripple Effect on European Biotech

In the past two years, a rapid succession of FDA policy shifts has fundamentally reshaped the regulatory landscape. These changes have created uncertainty for biotech companies around the world — lengthening development timelines, increasing demands for upfront capital, and amplifying modality-specific risks. European investors should now consider explicit regulatory strategies as essential to the success of their portfolio.

A Champions League of European Health Innovation Clusters

Recently at the Medicon Valley Alliance Summit in Copenhagen, the spotlight was on European competitiveness. In a keynote, panelists from four of Europe’s leading life sciences hubs shared their intention to establish a “Champions League” of clusters, working as a team to strengthen health innovation for Europe as a whole.

ATB Therapeutics: Antibody Seeker Missiles for Cancer and Autoimmune Diseases

Antibodies have long held promise as a ‘magic bullet’ for cancer therapies, yet many antibody-drug conjugates face issues with toxicity and resistance. Belgian startup ATB Therapeutics is producing a new type of weaponized antibodies, using plants as mini factories for safe, effective cancer and autoimmune treatments.

A New Horizon in Cancer Care: The Promise of Multi-Source Liquid Biopsies

For the many women who develop metastatic breast cancer, treatment options are increasingly determined using blood-based diagnostics. But there are many other bodily fluids that can also be screened, potentially opening doors to new therapies for these patients. This broader approach to testing could improve clinical trial designs and be extended to other cancer types.